Research ArticleArticle
Plasma Levels of Eicosapentaenoic Acid Are Associated with Anti-TNF Responsiveness in Rheumatoid Arthritis and Inhibit the Etanercept-driven Rise in Th17 Cell Differentiation in Vitro
Louisa Jeffery, Helena L. Fisk, Philip C. Calder, Andrew Filer, Karim Raza, Christopher D. Buckley, Iain McInnes, Peter C. Taylor and Benjamin A. Fisher
The Journal of Rheumatology February 2017, jrheum.161068; DOI: https://doi.org/10.3899/jrheum.161068
Louisa Jeffery
From the Rheumatology Research Group and Arthritis Research UK Rheumatoid Arthritis Pathogenesis Centre of Excellence (RACE), University of Birmingham, Birmingham; Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton; UK National Institute for Health Research (NIHR) Southampton Biomedical Research Centre, University Hospital Southampton National Health Service (NHS) Foundation Trust; University of Southampton, Southampton; Glasgow Biomedical Research Centre, University of Glasgow, Glasgow; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK. An unrestricted grant from Schering-Plough (now Merck) supported the clinical trial upon which this study is based. L. Jeffery, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; H.L. Fisk, BSc, Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, and University of Southampton; P.C. Calder, PhD, Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, and University of Southampton; A. Filer, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; K. Raza, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; C.D. Buckley, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; I. McInnes, PhD, Glasgow Biomedical Research Centre, University of Glasgow; P.C. Taylor, PhD, Kennedy Institute of Rheumatology, University of Oxford; B.A. Fisher, MD(Res), Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham. Address correspondence to Dr. B.A. Fisher, Rheumatology Research Group, Centre for Translational Inflammation Research, Queen Elizabeth Hospital Birmingham, Birmingham, B15 2WB, UK. E-mail: b.fisher@bham.ac.uk. Accepted for publication December 21, 2016.
Helena L. Fisk
From the Rheumatology Research Group and Arthritis Research UK Rheumatoid Arthritis Pathogenesis Centre of Excellence (RACE), University of Birmingham, Birmingham; Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton; UK National Institute for Health Research (NIHR) Southampton Biomedical Research Centre, University Hospital Southampton National Health Service (NHS) Foundation Trust; University of Southampton, Southampton; Glasgow Biomedical Research Centre, University of Glasgow, Glasgow; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK. An unrestricted grant from Schering-Plough (now Merck) supported the clinical trial upon which this study is based. L. Jeffery, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; H.L. Fisk, BSc, Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, and University of Southampton; P.C. Calder, PhD, Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, and University of Southampton; A. Filer, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; K. Raza, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; C.D. Buckley, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; I. McInnes, PhD, Glasgow Biomedical Research Centre, University of Glasgow; P.C. Taylor, PhD, Kennedy Institute of Rheumatology, University of Oxford; B.A. Fisher, MD(Res), Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham. Address correspondence to Dr. B.A. Fisher, Rheumatology Research Group, Centre for Translational Inflammation Research, Queen Elizabeth Hospital Birmingham, Birmingham, B15 2WB, UK. E-mail: b.fisher@bham.ac.uk. Accepted for publication December 21, 2016.
Philip C. Calder
From the Rheumatology Research Group and Arthritis Research UK Rheumatoid Arthritis Pathogenesis Centre of Excellence (RACE), University of Birmingham, Birmingham; Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton; UK National Institute for Health Research (NIHR) Southampton Biomedical Research Centre, University Hospital Southampton National Health Service (NHS) Foundation Trust; University of Southampton, Southampton; Glasgow Biomedical Research Centre, University of Glasgow, Glasgow; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK. An unrestricted grant from Schering-Plough (now Merck) supported the clinical trial upon which this study is based. L. Jeffery, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; H.L. Fisk, BSc, Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, and University of Southampton; P.C. Calder, PhD, Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, and University of Southampton; A. Filer, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; K. Raza, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; C.D. Buckley, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; I. McInnes, PhD, Glasgow Biomedical Research Centre, University of Glasgow; P.C. Taylor, PhD, Kennedy Institute of Rheumatology, University of Oxford; B.A. Fisher, MD(Res), Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham. Address correspondence to Dr. B.A. Fisher, Rheumatology Research Group, Centre for Translational Inflammation Research, Queen Elizabeth Hospital Birmingham, Birmingham, B15 2WB, UK. E-mail: b.fisher@bham.ac.uk. Accepted for publication December 21, 2016.
Andrew Filer
From the Rheumatology Research Group and Arthritis Research UK Rheumatoid Arthritis Pathogenesis Centre of Excellence (RACE), University of Birmingham, Birmingham; Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton; UK National Institute for Health Research (NIHR) Southampton Biomedical Research Centre, University Hospital Southampton National Health Service (NHS) Foundation Trust; University of Southampton, Southampton; Glasgow Biomedical Research Centre, University of Glasgow, Glasgow; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK. An unrestricted grant from Schering-Plough (now Merck) supported the clinical trial upon which this study is based. L. Jeffery, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; H.L. Fisk, BSc, Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, and University of Southampton; P.C. Calder, PhD, Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, and University of Southampton; A. Filer, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; K. Raza, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; C.D. Buckley, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; I. McInnes, PhD, Glasgow Biomedical Research Centre, University of Glasgow; P.C. Taylor, PhD, Kennedy Institute of Rheumatology, University of Oxford; B.A. Fisher, MD(Res), Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham. Address correspondence to Dr. B.A. Fisher, Rheumatology Research Group, Centre for Translational Inflammation Research, Queen Elizabeth Hospital Birmingham, Birmingham, B15 2WB, UK. E-mail: b.fisher@bham.ac.uk. Accepted for publication December 21, 2016.
Karim Raza
From the Rheumatology Research Group and Arthritis Research UK Rheumatoid Arthritis Pathogenesis Centre of Excellence (RACE), University of Birmingham, Birmingham; Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton; UK National Institute for Health Research (NIHR) Southampton Biomedical Research Centre, University Hospital Southampton National Health Service (NHS) Foundation Trust; University of Southampton, Southampton; Glasgow Biomedical Research Centre, University of Glasgow, Glasgow; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK. An unrestricted grant from Schering-Plough (now Merck) supported the clinical trial upon which this study is based. L. Jeffery, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; H.L. Fisk, BSc, Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, and University of Southampton; P.C. Calder, PhD, Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, and University of Southampton; A. Filer, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; K. Raza, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; C.D. Buckley, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; I. McInnes, PhD, Glasgow Biomedical Research Centre, University of Glasgow; P.C. Taylor, PhD, Kennedy Institute of Rheumatology, University of Oxford; B.A. Fisher, MD(Res), Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham. Address correspondence to Dr. B.A. Fisher, Rheumatology Research Group, Centre for Translational Inflammation Research, Queen Elizabeth Hospital Birmingham, Birmingham, B15 2WB, UK. E-mail: b.fisher@bham.ac.uk. Accepted for publication December 21, 2016.
Christopher D. Buckley
From the Rheumatology Research Group and Arthritis Research UK Rheumatoid Arthritis Pathogenesis Centre of Excellence (RACE), University of Birmingham, Birmingham; Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton; UK National Institute for Health Research (NIHR) Southampton Biomedical Research Centre, University Hospital Southampton National Health Service (NHS) Foundation Trust; University of Southampton, Southampton; Glasgow Biomedical Research Centre, University of Glasgow, Glasgow; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK. An unrestricted grant from Schering-Plough (now Merck) supported the clinical trial upon which this study is based. L. Jeffery, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; H.L. Fisk, BSc, Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, and University of Southampton; P.C. Calder, PhD, Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, and University of Southampton; A. Filer, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; K. Raza, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; C.D. Buckley, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; I. McInnes, PhD, Glasgow Biomedical Research Centre, University of Glasgow; P.C. Taylor, PhD, Kennedy Institute of Rheumatology, University of Oxford; B.A. Fisher, MD(Res), Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham. Address correspondence to Dr. B.A. Fisher, Rheumatology Research Group, Centre for Translational Inflammation Research, Queen Elizabeth Hospital Birmingham, Birmingham, B15 2WB, UK. E-mail: b.fisher@bham.ac.uk. Accepted for publication December 21, 2016.
Iain McInnes
From the Rheumatology Research Group and Arthritis Research UK Rheumatoid Arthritis Pathogenesis Centre of Excellence (RACE), University of Birmingham, Birmingham; Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton; UK National Institute for Health Research (NIHR) Southampton Biomedical Research Centre, University Hospital Southampton National Health Service (NHS) Foundation Trust; University of Southampton, Southampton; Glasgow Biomedical Research Centre, University of Glasgow, Glasgow; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK. An unrestricted grant from Schering-Plough (now Merck) supported the clinical trial upon which this study is based. L. Jeffery, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; H.L. Fisk, BSc, Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, and University of Southampton; P.C. Calder, PhD, Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, and University of Southampton; A. Filer, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; K. Raza, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; C.D. Buckley, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; I. McInnes, PhD, Glasgow Biomedical Research Centre, University of Glasgow; P.C. Taylor, PhD, Kennedy Institute of Rheumatology, University of Oxford; B.A. Fisher, MD(Res), Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham. Address correspondence to Dr. B.A. Fisher, Rheumatology Research Group, Centre for Translational Inflammation Research, Queen Elizabeth Hospital Birmingham, Birmingham, B15 2WB, UK. E-mail: b.fisher@bham.ac.uk. Accepted for publication December 21, 2016.
Peter C. Taylor
From the Rheumatology Research Group and Arthritis Research UK Rheumatoid Arthritis Pathogenesis Centre of Excellence (RACE), University of Birmingham, Birmingham; Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton; UK National Institute for Health Research (NIHR) Southampton Biomedical Research Centre, University Hospital Southampton National Health Service (NHS) Foundation Trust; University of Southampton, Southampton; Glasgow Biomedical Research Centre, University of Glasgow, Glasgow; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK. An unrestricted grant from Schering-Plough (now Merck) supported the clinical trial upon which this study is based. L. Jeffery, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; H.L. Fisk, BSc, Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, and University of Southampton; P.C. Calder, PhD, Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, and University of Southampton; A. Filer, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; K. Raza, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; C.D. Buckley, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; I. McInnes, PhD, Glasgow Biomedical Research Centre, University of Glasgow; P.C. Taylor, PhD, Kennedy Institute of Rheumatology, University of Oxford; B.A. Fisher, MD(Res), Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham. Address correspondence to Dr. B.A. Fisher, Rheumatology Research Group, Centre for Translational Inflammation Research, Queen Elizabeth Hospital Birmingham, Birmingham, B15 2WB, UK. E-mail: b.fisher@bham.ac.uk. Accepted for publication December 21, 2016.
Benjamin A. Fisher
From the Rheumatology Research Group and Arthritis Research UK Rheumatoid Arthritis Pathogenesis Centre of Excellence (RACE), University of Birmingham, Birmingham; Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton; UK National Institute for Health Research (NIHR) Southampton Biomedical Research Centre, University Hospital Southampton National Health Service (NHS) Foundation Trust; University of Southampton, Southampton; Glasgow Biomedical Research Centre, University of Glasgow, Glasgow; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK. An unrestricted grant from Schering-Plough (now Merck) supported the clinical trial upon which this study is based. L. Jeffery, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; H.L. Fisk, BSc, Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, and University of Southampton; P.C. Calder, PhD, Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, and University of Southampton; A. Filer, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; K. Raza, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; C.D. Buckley, PhD, Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham; I. McInnes, PhD, Glasgow Biomedical Research Centre, University of Glasgow; P.C. Taylor, PhD, Kennedy Institute of Rheumatology, University of Oxford; B.A. Fisher, MD(Res), Rheumatology Research Group and Arthritis Research UK RACE, University of Birmingham. Address correspondence to Dr. B.A. Fisher, Rheumatology Research Group, Centre for Translational Inflammation Research, Queen Elizabeth Hospital Birmingham, Birmingham, B15 2WB, UK. E-mail: b.fisher@bham.ac.uk. Accepted for publication December 21, 2016.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Plasma Levels of Eicosapentaenoic Acid Are Associated with Anti-TNF Responsiveness in Rheumatoid Arthritis and Inhibit the Etanercept-driven Rise in Th17 Cell Differentiation in Vitro
Louisa Jeffery, Helena L. Fisk, Philip C. Calder, Andrew Filer, Karim Raza, Christopher D. Buckley, Iain McInnes, Peter C. Taylor, Benjamin A. Fisher
The Journal of Rheumatology Feb 2017, jrheum.161068; DOI: 10.3899/jrheum.161068
Plasma Levels of Eicosapentaenoic Acid Are Associated with Anti-TNF Responsiveness in Rheumatoid Arthritis and Inhibit the Etanercept-driven Rise in Th17 Cell Differentiation in Vitro
Louisa Jeffery, Helena L. Fisk, Philip C. Calder, Andrew Filer, Karim Raza, Christopher D. Buckley, Iain McInnes, Peter C. Taylor, Benjamin A. Fisher
The Journal of Rheumatology Feb 2017, jrheum.161068; DOI: 10.3899/jrheum.161068